

# Validation of a health-related quality of life questionnaire in patients with recurrent *Clostridioides difficile* infection in ECOSPOR III, a Phase 3 randomized trial

Brittany Lapin PhD<sup>1</sup>, Kevin W Garey PharmD<sup>2</sup>; Henry Wu PhD<sup>3</sup>; Sissi V Pham PharmD<sup>4</sup>; Shirley P Huang PharmD MS<sup>4</sup>; Pat Ray Reese PhD<sup>5</sup>; Elaine Wang MD<sup>6</sup>; Abhishek Deshpande MD PhD<sup>1</sup>

<sup>1</sup>Cleveland Clinic, Cleveland, OH; <sup>2</sup>University of Houston, Houston, TX; <sup>3</sup>Consultant, CR Medicon, Piscataway, NJ; <sup>4</sup>AESARA, Inc., Chapel Hill, NC; <sup>5</sup>Consultant, Apex, NC; <sup>6</sup>Seres Therapeutics, Inc., Cambridge, MA

## Background

- *Clostridioides difficile* infection (CDI) is the leading cause of healthcare-associated diarrhea in the US
- Debilitating symptoms of CDI often lead to long-term effects on health-related quality-of-life (HRQOL)
- Garey et al developed a CDI-specific questionnaire, the *Clostridium difficile* Quality of Life Survey, Cdiff32, to measure physical, mental, and social health domains of HRQOL

## Objective

To establish the validity and responsiveness of Cdiff32 for patients with history of recurrent CDI enrolled in ECOSPOR III, regardless of treatment arm

## Methods

- Exploratory analysis of data from ECOSPOR III
- Patients with 3 or more CDI episodes within 12 months were screened; 182 patients with symptom resolution were randomized and completed Cdiff32 at baseline, week 1, and week 8
- Reliability and validity were evaluated based on COSMIN guidelines
  - Structural validity was assessed with confirmatory factor analysis
  - Convergent validity compared Cdiff32 to EQ-5D
  - Known groups validity compared responses across age and recurrence status at week 1
- Responsiveness was assessed in 134 patients without CDI recurrence by week 8


## Results

Table 1. Characteristics of Study Sample, n=182

Characteristics	Statistic
Age, mean ± sd	65.5 ± 16.5
Female Sex, %	59.9%
Body Mass Index (kg/m <sup>2</sup> ), mean ± sd	26.9 ± 6.7
Non-White, %	6.6%
<b>Patient-Reported Outcomes, mean ± sd</b>	
Baseline Cdiff32 Total Score	52.4 ± 18.4
Baseline EQ-5D Index	0.767 ± 0.175

- Structural validity was established with a 3-factor model fitting the data well (domains of mental, physical, and social relationships)
- High internal reliability with overall Cronbach's alpha = 0.94
- Convergent validity evidenced by significant correlations between similar Cdiff32 and EQ-5D domains (Pearson correlation coefficient ranged from 0.27-0.44, p<0.05 for all)

Figure 1. Known Groups Validity: Cdiff32 scores by week 1 recurrence status



\*p<0.05; n=8 patients did not complete Cdiff32 at 1 week. Vertical lines represent standard errors.

- Cdiff32 overall score and domain scores able to distinguish between age groups and recurrence status at week 1 (Figure 1)
- Internal responsiveness established for 134 patients without episodes of recurrent CDI from baseline to week 8: significant improvement across all domains (p<0.001 for all)

## Conclusions

- In our exploratory analysis, Cdiff32 questionnaire demonstrated validity, reliability and responsiveness to measure and compare HRQOL for patients with recurrent CDI
- Cdiff32 differentiated recurrent from non-recurrent patients and identified significant improvements after 8 weeks in patients without recurrence
- Minimal important differences in Cdiff32 can be approximated as 10 points
- Our findings highlight the negative impact of CDI on HRQOL, particularly mental health, and support the use of Cdiff32 in trials of patients with recurrent CDI

## Summary

- In a secondary analysis of 182 outpatients included in a Phase 3 clinical trial, reliability, validity, and responsiveness of a 32-item disease-specific questionnaire (Cdiff32) was established for patients with recurrent *Clostridioides difficile* infection

## Funding

This work was supported by Seres Therapeutics.

## References

- Garey KW, Aitken SL, Gschwind L, et al. Development and Validation of a *Clostridium difficile* Health-related Quality-of-Life Questionnaire. *J Clin Gastroenterol* 2016; 50(8): 631-7.
- Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. *Qual Life Res* 2010; 19(4): 539-49.